1. An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS2. Central Nervous System Complications of Human Immunodeficiency Virus Infection3. Health LIteracy in HIV-associated Neurocognitive Disorders4. Neuroimaging insights into the CNS effects of HIV infection5. Early and upstream subcellular organellar events associated with HAND6. White matter loss and oligodendrocyte dysfunction in HAND7. Pathogenesis of HIV-associated pain8. Neuropathogenesis of HIV-associated neuropathic pain9. Neuropathic Pain in HIV and the role of the Autophagy pathway10. Host peripheral immune dynamics increase HIV-associated neurocognitive disorders incidence and progression11. The role of immunometabolism in HIV associated depression and cognitive impairment12. Role of extracellular viral regulatory proteins in neuropathogenesis13. Role of inflammasomes in HIV-1 and drug abuse-mediated neuroinflammation14. The Contribution of Myeloid Cells to HIV Neuropathogenesis15. Immunophilin ligands modulate phagocytosis and viral replication in HIV-infected macrophages16. Immunometabolic mechanisms of HIV-associated neurocognitive disorders and traumatic brain injury: Commonalities and contrasts between chronic and acute neurodegenerative pathologies17. Endolysosome dysfunction in HAND18. Evolving biomarkers for HIV-associated neurocognitive disorders (HAND)19. Intracellular immunity against HIV infection20. NeuroHIV and the Glymphatic System21. The p75 neurotrophin receptor: emerging role in the pathogenesis of mature synapses in Human Immunodeficiency Virus-Associated Neurocognitive Disorders22. The Role of HIV-Associated Neuroendocrine Dysfunction in HAND23. Impact of SARS-CoV-2/COVID-19 on HIV-1-associated neurocognitive disorders24. Molecular mechanisms of dopaminergic transmission in NeuroHIV25. The effect of substance misuse on HIV persistence in the CNS: epidemiological, immunological, and molecular considerations26. Extracellular vesicles in alcohol- and tobacco-induced neuroAIDS27. NeuroHIV in the context of opioid use disorder: A complex and evolving relationship28. Impairment of cholesterol homeostasis induced by Nef-containing extracellular vesicles as a factor in HAND pathogenesis29. Long noncoding RNAs in immune response, viral infection, and opioid use30. Using cross-species behavioral tools to determine mechanisms contributing to HIV associated neurological disorders and comorbid substance use31. Therapeutic potential of Curcumin in treating HIV-1 associated neurocognitive disorders32. Targeting the Endocannabinoid System in HAND33. Predicting the effectiveness of combination treatment of Dolutegravir and Fluoxetine for Depressive disorders in HIV34. ANTIRETROVIRAL THERAPY AND ITS CEREBRAL VASCULAR TOXICITY35. Strategies for HIV-1 Elimination